Neridronate in the treatment of thalassemia-induced osteoporosis

MLA

Gaudio, Agostino, et al. Neridronate in the Treatment of Thalassemia-Induced Osteoporosis. Jan. 2005. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4ea57d3cda49af610dbe2c1ee9fbff6f&authtype=sso&custid=ns315887.

APA

Gaudio, A., Morabito, N., Lasco, A., Xourafa, A., Macri, , I, Atteritano, M., Catalano, A., Maisano, D., Morini, E., Franchina, F., Meo, A., & Frisina, N. (2005). Neridronate in the treatment of thalassemia-induced osteoporosis.

Chicago

Gaudio, Agostino, N Morabito, A Lasco, A Xourafa, , I Macri, M Atteritano, A Catalano, et al. 2005. “Neridronate in the Treatment of Thalassemia-Induced Osteoporosis,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4ea57d3cda49af610dbe2c1ee9fbff6f&authtype=sso&custid=ns315887.